| Item type |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2010-05-18 |
| タイトル |
|
|
タイトル |
<Original Article> A Proposal of Effctive Immunochemotherapy Using Recombinant Interleukin 2 and Adriamycin, and Its Theoretical Background |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
言語 |
en |
|
主題 |
Immunochemotherapy |
| キーワード |
|
|
言語 |
en |
|
主題 |
Recombinant interleukin 2 |
| キーワード |
|
|
言語 |
en |
|
主題 |
Adriamycin |
| キーワード |
|
|
言語 |
en |
|
主題 |
Liver cancer |
| キーワード |
|
|
言語 |
en |
|
主題 |
Surface marker |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| ID登録 |
|
|
ID登録 |
10.34429/00003189 |
|
ID登録タイプ |
JaLC |
| 著者名 |
YAMAMOTO, Yasuyoshi
IIZUKA, Hidehiko
YAMAMOTO, Masayuki
TASAKA, Kachio
SUGAHARA, Katsuhiko
|
| 内容 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
We performed immunochemotherapy using a continuous infusion of recombinant interleukin 2 (IL2) and intermittent one-shot-injections of Adriamycin (ADR) administered directly to the hepatic artery in 6 cases of advanced hepatocellular carcinoma (HCC). Although the observation periods were short, the tumors reduced in size; most notably, a massive tumor in the right lobe disappeared in one case. After reviewing the 6 patients with HCC, we demonstrated a possible cause of ADR as a kind of immuno-modifier. In an in vitro study, the susceptibility of subpopulations of lymphocytes to ADR was variable with the suppressor T cell being more susceptible to ADR compared to the helper T cell. In HCC patients, the ratio of the suppressor T cells to the helper T cells (suppressor/helper ratio) was significantly higher than that of the healthy controls. Thus, following the administration of the optimal dose of ADR, specific decrease in the suppressor T cell and increase in the helper T cell in response to ADR can be obtained for the recovery of the suppressor/helper ratio. Moreover, ADR-treated lymphocytes of HCC patients exhibited constant killer activity in the presence of IL2. Although the optimal dose of ADR for clinical use may be within a very narrow range, ADR combined with IL2 following tumor mass-reduction treatments may restore the immunity of advanced HCC patients and prolong their survival. |
|
言語 |
en |
| 出版者 |
|
|
出版者 |
山梨医科大学医学会 |
|
言語 |
ja |
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
0912-0025 |
| NCID |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AN10044054 |
| 書誌情報 |
ja : 山梨医科大学雑誌
en : Yamanashi medical journal
巻 5,
号 1,
p. 25-34,
発行日 1990
|
| 著者版フラグ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
AN10044054_05_01_03.pdf (1.6 MB)
